Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Inovio Pharmaceuticals Inc.

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, gained 0.43% in pre-ma...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/8/2026

Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Innodata Inc. ($INOD), PAR Technolog...

3 Small-Cap Tech Stocks Rated ‘Strong Buy’ with Triple-Digit Upside

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, lost 0.03% in pre-mark...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/7/2026

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, closed 0.16% higher on...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/3/2026

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, lost 0.23% in pre-mark...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/2/2026

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, lost 0.20% in pre-mark...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 4/1/2026

An update from Virgin Wines UK PLC ( ($GB:VINO) ) is now available. Virgin Wines UK plc has confirmed that as of 31 March 2026 its issued share cap...

Virgin Wines updates market on total voting rights and share capital

Gaucho Group Holdings ( ($VINO) ) just unveiled an update. On March 18, 2026, Gaucho Group Holdings provided a corporate update to its stockholders...

Gaucho Group Issues Investor Corporate Update to Stockholders

The Schwab U.S. Dividend Equity ETF (SCHD), which tracks high-dividend U.S. stocks in the Dow Jones U.S. Dividend 100 Index, gained 0.82% in pre-ma...

Schwab U.S. Dividend Equity ETF (SCHD) Daily Update, 3/31/2026

Wells Fargo analyst maintained a Hold rating on HF Sinclair Corporation today and set a price target of $67.00. In addition to Wells Fargo, HF Sinc...

Wells Fargo Reaffirms Their Hold Rating on HF Sinclair Corporation (DINO)

Schroder UK Public Private Trust ( ($GB:INOV) ) has provided an update. Schroders Capital Global Innovation Trust plc has shifted fully to an order...

Schroders Capital Global Innovation Trust Steps Up Cash Returns in Managed Wind-Down

A class action lawsuit was filed against Inovio Pharmaceuticals ($INO) on February 6, 2026. Plaintiffs – shareholders – in the federal securities c...

Shareholders Sue Inovio Pharmaceuticals Over DNA Technology Claims

Wall Street’s leading research firm, Goldman Sachs ($GS), has named three U.S. oil refiners as top sector picks: Valero Energy ($VLO), HF Sinclair ...

Goldman Sachs Names 3 Top Oil Stocks to Buy amid Middle East Tensions

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Inovio Pharmaceuticals, with a price target of $6.00. Ten...

Piper Sandler Sticks to Its Buy Rating for Inovio Pharmaceuticals (INO)

Innodata ( ($INOD) ) has issued an update. On March 9, 2026, Innodata Inc. entered into a new employment agreement with President and Chief Revenue...

Current Quarter	$-0.3	Next Quarter	$-0.31
Current Year	$-1.12	Next Year	$-0.62
QoQ Growth	-3.3%	YoY Growth	+44.6%
3Y EPS CAGR	+39.0%	Target Price	$7.63
Consensus	Buy	Upside	+600.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INO	$1.09	+3.81%	2.69M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INO	$1.09	+3.8%	2.69M
3
4
5
6

INO

INO

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Inovio Pharmaceuticals Inc. Data in Excel

Get Inovio Pharmaceuticals Inc. Data in Excel